唑来膦酸预防减重手术后骨与肌肉丢失(ZABAS)——一项随机对照试验的研究方案
本研究为随机双盲安慰剂对照试验,计划纳入60名35岁及以上肥胖男女,在Roux-en-Y胃旁路术或袖状胃切除术前3周随机给予唑来膦酸5 mg(溶于100 ml等渗盐水)或安慰剂(仅100 ml等渗盐水),术后12和24个月随访,主要结局为定量CT评估的腰椎体积骨密度变化。
要点
- 唑来膦酸5 mg或安慰剂在减重手术前3周给药,术后12和24个月评估。
- 主要结局为腰椎体积骨密度变化,次要结局包括股骨近端体积骨密度及肌肉相关指标。
- 研究结果旨在为减重手术患者的循证照护提供依据。
核心结论
- 本研究旨在探究唑来膦酸对减重手术后骨与肌肉丢失的预防作用,结果将为减重手术患者的循证照护提供依据。
研究设计与样本
- 随机双盲安慰剂对照试验,计划纳入60名35岁及以上肥胖男女,随机接受唑来膦酸5 mg(溶于100 ml等渗盐水)或安慰剂(仅100 ml等渗盐水),术前3周给药,术后12和24个月随访。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bariatric surgery has adverse effects on the muscular-skeletal system with loss of bone mass and muscle mass and an increase in the risk of fracture. Zoledronic acid is widely used in osteoporosis and prevents bone loss and fracture. Bisphosphonates may also have positive effects on skeletal muscle. The aim of this study is to investigate the effects of zoledronic acid for the prevention of bone and muscle loss after bariatric surgery. METHODS/DESIGN: This is a randomized double-blind placebo-controlled study. Sixty women and men with obesity aged 35 years or older will complete baseline assessments before randomization to either zoledronic acid (5 mg in 100 ml isotonic saline) or placebo (100 ml isotonic saline only) 3 weeks before surgery with Roux-en-Y-gastric bypass (RYGB) or sleeve gastrectomy (SG). Follow-up assessments are performed 12 and 24 months after surgery. The primary outcome is changes in lumbar spine volumetric bone mineral density (vBMD) assessed by quantitative computed tomography (QCT). Secondary bone outcomes are changes in proximal femur vBMD assessed by QCT. Changes in cortical and trabecular bone microarchitecture and estimated bone strength will be assessed by high-resolution peripheral quantitative computed tomography (HR-pQCT). Cortical material bone strength at the mid-tibia diaphysis will be assessed using microindentation and fasting blood samples will be obtained to assess biochemical markers of bone turnover and calcium metabolism. Secondary muscle outcomes include whole body lean mass assessed using dual-energy X-ray absorptiometry. Dynamometers will be used to assess handgrip, shoulder, ankle, and knee muscle strength. Short Physical Performance Battery, 7.6-m walking tests, 2-min walking test, and a stair climb test will be assessed as biomarkers of physical function. Self-reported physical activity level is assessed using International Physical Activity Questionnaire (IPAQ). DISCUSSION: Results from this study will be instrumental for the evidence-based care of patients undergoing bariatric surgery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04742010. Registered on 5 February 2021.
引用
- Gam S, Gram B, Juhl CB, et al. Zoledronic Acid for prevention of bone and muscle loss after BAriatric Surgery (ZABAS)-a study protocol for a randomized controlled trial. Trials. 2022. PMID: 36209245. doi:10.1186/s13063-022-06766-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。